<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

	<!-- RSS feed defaults -->
	<channel>
		<title>Wyss InstituteDrug Development &#8211; Wyss Institute</title>
		<link>https://wyss.stage.a17.io</link>
		<description>Wyss Institute at Harvard</description>
		<lastBuildDate>Thu, 30 Jul 2026 21:38:59 +0000</lastBuildDate>
		<language>en-US</language>
		<sy:updatePeriod>hourly</sy:updatePeriod>
		<sy:updateFrequency>1</sy:updateFrequency>
		<atom:link href="https://wyss.stage.a17.io/application-area/drug-development/feed/" rel="self" type="application/rss+xml" />

		<generator>https://wordpress.org/?v=6.9.6</generator>

		<!-- Start loop -->
		
			<item>
				<title>CRISPR&#8217;s Impact, Today</title>
				<link>https://wyss.stage.a17.io/news/crisprs-impact-today/</link>
        <pubDate>Mon, 21 Oct 2024 12:00:08 +0000</pubDate>
        <dc:creator><![CDATA[Mariel Schoen]]></dc:creator>
        		<category><![CDATA[Translation News]]></category>
		<category><![CDATA[CRISPR]]></category>
		<category><![CDATA[Editas Inc.]]></category>
		<category><![CDATA[eGenesis]]></category>
		<category><![CDATA[George Church]]></category>
		<category><![CDATA[Massachusetts General Hospital]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?p=40926</guid>
                            <description>Keeping CRISPR’s promise for patients in need</description>
                                        <content:encoded><![CDATA[<p>By Seth Kroll (BOSTON) &mdash; In the not&#x2d;so&#x2d;distant past, CRISPR, the revolutionary gene&#x2d;editing technology, was discovered as a defense system protecting bacteria against viruses. Today, with the persistence and ingenuity of many scientists, it is no longer just the subject of fascinating academic research papers and speculative discussions on its future usefulness for medicine.</p>
<p><a href="https://wyss.stage.a17.io/news/crisprs-impact-today/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.stage.a17.io/news/crisprs-impact-today/</link>
          <title>Slayman with (left to right) Dr. Leo Riella, Medical Director of Kidney Transplantation, Dr. Nahel Elias, Interim Chief, Division of Transplant Surgery, his partner, Faren, and Dr. Tatsuo Kawai, Director, Legorreta Center for Clinical Transplant Tolerance. CREDITS: Michelle Rose/Massachusetts General Hospital</title>
					<url>https://wyss-stage.imgix.net/app/uploads/2024/09/09093712/20240403_mcr_transplant_patient_010-1.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=911871f7428259dbd6ffadedb29de92e"/></url>
				</image>
        			</item>

		
			<item>
				<title>DNA Nanoswitch Calipers for Single-Molecule Proteomics</title>
				<link>https://wyss.stage.a17.io/technology/dna-nanoswitch-calipers-for-single-molecule-proteomics/</link>
        <pubDate>Tue, 15 Oct 2024 16:48:31 +0000</pubDate>
        <dc:creator><![CDATA[Jessica Leff]]></dc:creator>
        		<category><![CDATA[Boston Children's Hospital]]></category>
		<category><![CDATA[Dana-Farber Cancer Institute]]></category>
		<category><![CDATA[DNA Nanoswitches]]></category>
		<category><![CDATA[Harvard Medical School]]></category>
		<category><![CDATA[Nanoswitch]]></category>
		<category><![CDATA[Origami]]></category>
		<category><![CDATA[Wesley Wong]]></category>
		<category><![CDATA[William Shih]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?post_type=technology&#038;p=41172</guid>
                                                <content:encoded><![CDATA[<p>Proteins are well known as essential orchestrators of life, but what is less well&#x2d;understood is their post&#x2d;translational modifications (PTMs). These modifications can include the attachment of chemical groups, carbohydrates, or lipids to the proteins, which affect their folding, stability, and functions. Certain protein PTMs have been linked to diabetes, cancer, and neurodegenerative disease&#8230;</p>
<p><a href="https://wyss.stage.a17.io/technology/dna-nanoswitch-calipers-for-single-molecule-proteomics/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.stage.a17.io/technology/dna-nanoswitch-calipers-for-single-molecule-proteomics/</link>
          <title>Credit: Envato/vladimirzotov</title>
					<url>https://wyss-stage.imgix.net/app/uploads/2024/10/10123749/3d-illustration-atom-connection-concept-abstrack-2024-09-23-03-15-30-utc.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=65105e8acc5c854b2d6f15d747532acc"/></url>
				</image>
        			</item>

		
			<item>
				<title>“Suspended animation” drug could aid organ transplantation and survival from traumatic injury</title>
				<link>https://wyss.stage.a17.io/news/suspended-animation-drug-could-aid-organ-transplantation-and-survival-from-traumatic-injury/</link>
        <pubDate>Tue, 24 Sep 2024 14:50:33 +0000</pubDate>
        <dc:creator><![CDATA[Jessica Leff]]></dc:creator>
        		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Biostasis]]></category>
		<category><![CDATA[DARPA]]></category>
		<category><![CDATA[Donald E. Ingber]]></category>
		<category><![CDATA[Gene Expression]]></category>
		<category><![CDATA[Injectable]]></category>
		<category><![CDATA[Metabolic Engineering]]></category>
		<category><![CDATA[Tissue Regeneration]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?p=39093</guid>
                            <description>Study suggests that a pain relief drug can quickly and reversibly induce a sleep-like state in cells and organs could facilitate organ transplantation and prevent irreversible tissue injury</description>
                                        <content:encoded><![CDATA[<p>(CAMBRIDGE, UK) &ndash; Researchers have shown that a non&#x2d;addictive pain relief drug could be used to preserve cells and organs quickly and safely for transplantation, removing the need for static cold storage. The research, published today in eLife, was described by the editors as an important study providing solid evidence that the existing drug, SNC80, can rapidly and reversibly slow biochemical&#8230;</p>
<p><a href="https://wyss.stage.a17.io/news/suspended-animation-drug-could-aid-organ-transplantation-and-survival-from-traumatic-injury/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.stage.a17.io/news/suspended-animation-drug-could-aid-organ-transplantation-and-survival-from-traumatic-injury/</link>
          <title>Caption. Credit: Envato/Chalabala</title>
					<url>https://wyss-stage.imgix.net/app/uploads/2024/02/05152449/emergency-medical-service-2023-11-27-04-57-42-utc.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=d122e344c2692b34c68f3e8dffa33317"/></url>
				</image>
        			</item>

		
			<item>
				<title>Ropirio: Novel Treatments Targeting the Lymphatic System</title>
				<link>https://wyss.stage.a17.io/technology/ropirio-novel-treatments-targeting-the-lymphatic-system/</link>
        <pubDate>Wed, 11 Sep 2024 13:56:37 +0000</pubDate>
        <dc:creator><![CDATA[Mariel Schoen]]></dc:creator>
        		<category><![CDATA[Boston University]]></category>
		<category><![CDATA[Christopher Chen]]></category>
		<category><![CDATA[Inflammation]]></category>
		<category><![CDATA[Sangeeta Bhatia]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?post_type=technology&#038;p=40951</guid>
                            <description><a href="https://www.ropirio.com/">Ropirio Therapeutics</a> is developing the world’s first drug that directly targets and reactivates lymph vessels, and a platform for discovering more.</description>
                                        <content:encoded><![CDATA[<p>The human lymphatic system is vast and critical to our health, including the proper functioning of our immune system. Over the last decade, research into the lymph system has revealed its dysfunction in a wide variety of diseases, but development of drugs to directly target the lymph system has lagged, in part because there are few reliable preclinical models of lymph vessels on which to test drug&#8230;</p>
<p><a href="https://wyss.stage.a17.io/technology/ropirio-novel-treatments-targeting-the-lymphatic-system/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.stage.a17.io/technology/ropirio-novel-treatments-targeting-the-lymphatic-system/</link>
          <title>The human body's lymphatic system is a critical network that allows proper functioning of the immune system and movement of fluids, but it can become impaired due to inflammation. Ropirio is developing novel medicines that directly target the lymph vessels to treat a number of diseases. Credit: Envato Elements</title>
					<url>https://wyss-stage.imgix.net/app/uploads/2024/09/09161236/doctor-checking-size-of-lymph-nodes-2023-11-27-05-27-54-utc.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=92d9a9e9aef3c38e0d004eb18b52f388"/></url>
				</image>
        			</item>

		
			<item>
				<title>Ropirio launches from Wyss Institute to develop first-in-class lymphatic medicines</title>
				<link>https://wyss.stage.a17.io/news/ropirio-launches-from-wyss-institute-to-develop-first-in-class-lymphatic-medicines/</link>
        <pubDate>Wed, 11 Sep 2024 13:55:12 +0000</pubDate>
        <dc:creator><![CDATA[Mariel Schoen]]></dc:creator>
        		<category><![CDATA[Translation News]]></category>
		<category><![CDATA[Boston University]]></category>
		<category><![CDATA[Christopher Chen]]></category>
		<category><![CDATA[Inflammation]]></category>
		<category><![CDATA[Sangeeta Bhatia]]></category>
		<category><![CDATA[Technology Translation]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?p=40940</guid>
                            <description>The company is leveraging a discovery program developed at Harvard and Boston University to treat a wide range of serious diseases </description>
                                        <content:encoded><![CDATA[<p>By Lindsay Brownell (BOSTON) &mdash; The Wyss Institute at Harvard University announced today that Ropirio Therapeutics, Inc. (Ropirio) has secured a worldwide, exclusive license from Harvard&rsquo;s Office of Technology Development (OTD) and Boston University (BU)&rsquo;s Technology Development office for novel molecules that activate the lymphatic system &ndash; a first in the pharma industry. &ldquo;There has been a&#8230;</p>
<p><a href="https://wyss.stage.a17.io/news/ropirio-launches-from-wyss-institute-to-develop-first-in-class-lymphatic-medicines/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.stage.a17.io/news/ropirio-launches-from-wyss-institute-to-develop-first-in-class-lymphatic-medicines/</link>
          <title>The human body's lymphatic system is a critical network that allows proper functioning of the immune system and movement of fluids, but it can become impaired due to inflammation. Ropirio is developing novel medicines that directly target the lymph vessels to treat a number of diseases. Credit: Envato Elements</title>
					<url>https://wyss-stage.imgix.net/app/uploads/2024/09/09161236/doctor-checking-size-of-lymph-nodes-2023-11-27-05-27-54-utc.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=92d9a9e9aef3c38e0d004eb18b52f388"/></url>
				</image>
        			</item>

		
			<item>
				<title>Alzheimer’s drug may someday help save lives by inducing a state of “suspended animation”</title>
				<link>https://wyss.stage.a17.io/news/alzheimers-drug-may-someday-help-save-lives-by-inducing-a-state-of-suspended-animation/</link>
        <pubDate>Thu, 22 Aug 2024 15:25:07 +0000</pubDate>
        <dc:creator><![CDATA[Jessica Leff]]></dc:creator>
        		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Biostasis]]></category>
		<category><![CDATA[Donald E. Ingber]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?p=40410</guid>
                            <description>New research in tadpoles reveals that FDA-approved donepezil puts the animals in reversible torpor-like state </description>
                                        <content:encoded><![CDATA[<p>By Lindsay Brownell (BOSTON) &mdash; Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University report that they were able to successfully put tadpoles of Xenopus laevis frogs into a hibernation&#x2d;like torpor state using donepezil (DNP), a drug approved by the FDA to treat Alzheimer&rsquo;s. The team had previously used another drug, SNC80, to achieve similar results in&#8230;</p>
<p><a href="https://wyss.stage.a17.io/news/alzheimers-drug-may-someday-help-save-lives-by-inducing-a-state-of-suspended-animation/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.stage.a17.io/news/alzheimers-drug-may-someday-help-save-lives-by-inducing-a-state-of-suspended-animation/</link>
          <title></title>
					<url>https://wyss-stage.imgix.net/app/uploads/2022/09/26143549/Unravel-Biosciences_Tadpole_crop-e1664217399832.jpeg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=7e7e97b60daac80588c17aa5e02e4077"/></url>
				</image>
        			</item>

		
			<item>
				<title>A better way to make RNA drugs</title>
				<link>https://wyss.stage.a17.io/news/a-better-way-to-make-rna-drugs/</link>
        <pubDate>Fri, 12 Jul 2024 09:00:40 +0000</pubDate>
        <dc:creator><![CDATA[Jessica Leff]]></dc:creator>
        		<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[George Church]]></category>
		<category><![CDATA[Northpond]]></category>
		<category><![CDATA[RNA]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?p=39895</guid>
                            <description>New enzymatic synthesis method developed at Wyss Institute expands RNA therapeutic capabilities while eliminating toxic byproducts of standard chemical synthesis</description>
                                        <content:encoded><![CDATA[<p>By Lindsay Brownell (BOSTON) &mdash; While the COVID&#x2d;19 vaccines introduced many people to RNA&#x2d;based medicines, oligonucleotides have already been on the market for years to treat diseases like Duchenne Muscular Dystrophy and amyloidosis. RNA therapies offer many advantages over traditional small molecule drugs, including their ability to address almost any genetic component within cells and to guide&#8230;</p>
<p><a href="https://wyss.stage.a17.io/news/a-better-way-to-make-rna-drugs/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.stage.a17.io/news/a-better-way-to-make-rna-drugs/</link>
          <title>Single-stranded RNA is a valuable basis for new drugs, but chemically synthesizing it is costly and damaging to the environment. A new enzymatic RNA synthesis method developed at the Wyss offers a better solution. Credit: Shutterstock</title>
					<url>https://wyss-stage.imgix.net/app/uploads/2019/10/10142259/RNA_shutterstock_1203487687.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=b07e54bbae4a1dd66f3aa98386185b80"/></url>
				</image>
        			</item>

		
			<item>
				<title>AminoX: Making Better Protein Drugs, Quicker and Cheaper</title>
				<link>https://wyss.stage.a17.io/media-post/aminox-making-better-protein-drugs-quicker-and-cheaper/</link>
        <pubDate>Wed, 10 Jul 2024 13:56:00 +0000</pubDate>
        <dc:creator><![CDATA[Jessica Leff]]></dc:creator>
        		<category><![CDATA[Donald E. Ingber]]></category>
		<category><![CDATA[George Church]]></category>
		<category><![CDATA[Harvard Medical School]]></category>
		<category><![CDATA[Immune System]]></category>
		<category><![CDATA[James J. Collins]]></category>
		<category><![CDATA[MIT]]></category>
		<category><![CDATA[Protein Engineering]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?post_type=media_post&#038;p=40393</guid>
                                                <content:encoded><![CDATA[<p>A synthetic biology and advanced chemistry platform that efficiently incorporates non&#x2d;standard amino acids by hacking the ubiquitous protein synthesis process. Credit: Wyss Institute at Harvard University&#8230;</p>
<p><a href="https://wyss.stage.a17.io/media-post/aminox-making-better-protein-drugs-quicker-and-cheaper/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.stage.a17.io/media-post/aminox-making-better-protein-drugs-quicker-and-cheaper/</link>
          <title></title>
					<url>https://wyss-stage.imgix.net/app/uploads/2024/07/10095538/Video-Thumbnail-AminoX-No-Text.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=c4bd9cd62f212831fb0068e8a9918029"/></url>
				</image>
        			</item>

		
			<item>
				<title>Justin Scott on Engineering Proteins for Real-World Impact</title>
				<link>https://wyss.stage.a17.io/news/justin-scott-on-engineering-proteins-for-real-world-impact/</link>
        <pubDate>Wed, 26 Jun 2024 15:05:06 +0000</pubDate>
        <dc:creator><![CDATA[Jessica Leff]]></dc:creator>
        		<category><![CDATA[Community]]></category>
		<category><![CDATA[Humans of the Wyss]]></category>
		<category><![CDATA[Protein Engineering]]></category>
		<category><![CDATA[Women's Health]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?p=40307</guid>
                                                <content:encoded><![CDATA[<p>The Humans of the Wyss (HOW) series features members of the Wyss community discussing their work, the influences that shape them as professionals, and their collaborations at the Wyss Institute and beyond. Years ago, Justin Scott was working in finance when a conversation with a friend who cared deeply about their science&#x2d;related job prompted him to make a change. Chasing that same job&#8230;</p>
<p><a href="https://wyss.stage.a17.io/news/justin-scott-on-engineering-proteins-for-real-world-impact/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.stage.a17.io/news/justin-scott-on-engineering-proteins-for-real-world-impact/</link>
          <title>Justin Scott, Scientist I. Credit: Wyss Institute at Harvard University</title>
					<url>https://wyss-stage.imgix.net/app/uploads/2024/06/26110347/HoW-Justin-Scott-00632.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=c502c3ee1f93bff7f6a959414ada24d9"/></url>
				</image>
        			</item>

		
			<item>
				<title>The Wyss Institute’s 2024-2025 Validation Projects</title>
				<link>https://wyss.stage.a17.io/news/the-wyss-institutes-2024-2025-validation-projects/</link>
        <pubDate>Wed, 29 May 2024 14:55:23 +0000</pubDate>
        <dc:creator><![CDATA[Jessica Leff]]></dc:creator>
        		<category><![CDATA[Awards]]></category>
		<category><![CDATA[Community]]></category>
		<category><![CDATA[Research Spotlights]]></category>
		<category><![CDATA[Technology Translation]]></category>
				<guid isPermaLink="false">https://wyss.harvard.edu/?p=40101</guid>
                            <description>15 projects named to this year’s class of technologies with high potential for positive impact </description>
                                        <content:encoded><![CDATA[<p>Every year the Wyss Institute names a class of Validation Projects whose teams receive dedicated funding, business development support, and other resources to advance their promising technologies towards commercialization. They also collaborate with key opinion leaders, investors, and potential customers to de&#x2d;risk their innovations and speed their progress to the market. This year&#8230;</p>
<p><a href="https://wyss.stage.a17.io/news/the-wyss-institutes-2024-2025-validation-projects/" rel="nofollow">Source</a></p>]]></content:encoded>
                                    
				<image>
          <link>https://wyss.stage.a17.io/news/the-wyss-institutes-2024-2025-validation-projects/</link>
          <title>Associate Faculty member Natalie Artzi and Postdoctoral Fellow Maria Poley are part of a Validation Project team developing brain-targeted nanoparticles to improve the treatment of brain diseases. Credit: Wyss Institute at Harvard University</title>
					<url>https://wyss-stage.imgix.net/app/uploads/2024/05/28130127/Natalie-Artzi-and-Maria-Poley_Neutral-04910.jpg?auto=format%2Ccompress&#038;crop=faces%2Centropy&#038;fit=crop&#038;h=400&#038;q=50&#038;w=300&#038;s=eb7214cf070fda4c6d10a2aabeb39223"/></url>
				</image>
        			</item>

			</channel>
</rss>
